Therefore, a patient with a presumed diagnosis of XLH presenting with hypercalciuria should never be started on conventional treatment (phosphate supplements and active vitamin D) or burosumab—an FGF23 antibody—as this may promote progressive nephrocalcinosis. Here, FGF23 is linked to nephrocalcinosis.